Are PEGylated liposomes better than conventional liposomes? A special case for vincristine

References

• Albanese A, Tang PS, Chan WC. (2012). The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14:1–16
   PubMed Web of Science ®Google Scholar
• Allen TM, Newman MS, Woodle MC, et al. (1995). Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 62:199–204
   PubMed Web of Science ®Google Scholar
• Aminoff D, Bruegge WF, Bell WC, et al. (1977). Role of sialic acid in survival of erythrocytes in the circulation: interaction of neuraminidase-treated and untreated erythrocytes with spleen and liver at the cellular level. Proc Natl Acad Sci USA 74:1521–4
   PubMed Web of Science ®Google Scholar
• Baguley BC, Holdaway KM, Thomsen LL, et al. (1991). Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27:482–7
   PubMed Web of Science ®Google Scholar
• Bandak S, Goren D, Horowitz A, et al. (1999). Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 10:911–20
   PubMed Web of Science ®Google Scholar
• Barenholz Y. (2012). Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release 160:117–34
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Papadopoulos NE, Kim KB, et al. (2008). A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Melanoma Res 18:400–4
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Sato T, Kim KB, et al. (2009). Phase II study of vincristine sulfate liposomes injection in patients with metastatic uveal melanoma. J Clin Oncol (2009 ASCO Annual Meeting) 27:15
   Google Scholar
• Boman NL, Masin D, Mayer LD, et al. (1994). Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54:2830–3
   PubMed Web of Science ®Google Scholar
• Boman NL, Mayer LD, Cullis PR. (1993). Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta 1152:253–8
   PubMed Web of Science ®Google Scholar
• Bratosin D, Mazurier J, Tissier JP, et al. (1998). Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages: a review. Biochimie 80:173–95
   PubMed Web of Science ®Google Scholar
• Carbone PP, Vincent B, Frei E III, Brindley CO. (1963). Clinical studies with vincristine. Blood 21:640–7
   PubMed Web of Science ®Google Scholar
• Cattel L, Ceruti M, Dosio F. (2003). From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 89:237–49
   PubMed Web of Science ®Google Scholar
• Chow DD, Essien HE, Padki MM, Hwang KJ. (1989). Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect. J Pharmacol Exp Ther 248:506–13
   PubMed Web of Science ®Google Scholar
• Cui J, LiC, Wang C, et al. (2011). Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage? J Pharm Sci 100:2835–48
   PubMed Web of Science ®Google Scholar
• Damen J, Regts J, Scherphof G. (1981). Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition. Biochim Biophys Acta 665:538–45
   PubMed Web of Science ®Google Scholar
• Dams ET, Laverman P, Oyen WJ, et al. (2000). Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292:1071–9
   PubMed Web of Science ®Google Scholar
• Embree L, Gelmon K, Tolcher A, et al. (1997). Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41:347–52
   Web of Science ®Google Scholar
• Gelmon KA, Tolcher A, Diab AR, et al. (1999). Phase I study of liposomal vincristine. J Clin Oncol 17:697–705
   PubMed Web of Science ®Google Scholar
• Hennig R, Pollinger K, Veser A, et al. (2014). Nanoparticle multivalency counterbalances the ligand affinity loss upon PEGylation. J Control Release 194:20–7
   PubMed Web of Science ®Google Scholar
• Himes RH. (1991). Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 51:257–67
   PubMed Web of Science ®Google Scholar
• Hitoshi Y, ToshiroY, Takashi K, et al. (1995). Effects of sialic acid derivative on long circulation time and tumor concentration of liposomes. Int J Pharm 113:141–8
   Web of Science ®Google Scholar
• Jensen GM, Bunch T. (2007). Conventional liposome performance and evaluation: lessons from the development of Vescan. J Liposome Res 17:121–37
   PubMed Web of Science ®Google Scholar
• Johnson IS, Armstrong J, Gorman M, Burnett JP Jr. (1963). The vinca alkaloids: a new class of oncolytic agents. Cancer Res 23:1390–427
   PubMed Web of Science ®Google Scholar
• Johnston MJ, Semple SC, Klimuk SK, et al. (2006). Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta 1758:55–64
   PubMed Web of Science ®Google Scholar
• Johnston MJ, Semple SC, Klimuk SK, et al. (2007). Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta 1768:1121–7
   PubMed Web of Science ®Google Scholar
• Jordan MA, Thrower D, Wilson L. (1991). Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 51:2212–22
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Deitcher S, Silverman JA, Morgan G. (2014). Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy. Clin Lymphoma Myeloma Leuk 14:37–42
   PubMed Web of Science ®Google Scholar
• Kirby C, Gregoriadis G. (1983). The effect of lipid composition of small unilamellar liposomes containing melphalan and vincristine on drug clearance after injection into mice. Biochem Pharmacol 32:609–15
   PubMed Web of Science ®Google Scholar
• Krishna R, Webb M, St Onge, Mayer LD. (2001). Liposomal and non-liposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther 298:1206–12
   PubMed Web of Science ®Google Scholar
• Laverman P, Carstens M, Boerman OC, et al. (2001). Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 298:607–12
   PubMed Web of Science ®Google Scholar
• Layton D, Trouet A. (1980). A comparison of the therapeutic effects of free and liposomally encapsulated vincristine in leukemic mice. Eur J Cancer 16:945–50
   PubMed Web of Science ®Google Scholar
• Lee JH, Nan A. (2012). Combination drug delivery approaches in metastatic breast cancer. Drug Deliv, Early Online: 1-17. doi: http://dx.doi.org/10.1155/2012/915375
   PubMed Web of Science ®Google Scholar
• Leo A, Hansch C, Elkins D. (1971). Partition coefficients and their uses. Chem Rev 71:525–616
   Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–84
   PubMed Web of Science ®Google Scholar
• Mayer LD, Bally M, Loughrey H, et al. (1990). Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50:575–9
   PubMed Web of Science ®Google Scholar
• Namba Y, Sakakibara T, Masada M, et al. (1990). Glucuronate-modified liposomes with prolonged circulation time. Chem Pharm Bull 38:1663–6
   PubMed Web of Science ®Google Scholar
• Nelson RL, Dyke RW, Root MA. (1977). Comparative pharmacokinetics of the vinca alkaloids in man. Clin Pharmacol Ther 21:112
   Web of Science ®Google Scholar
• Nishiya T, Lam R, Eng F, et al. (1995). Mechanistic study on toxicity of positively charged liposomes containing stearylamine to blood. Artif Cells Blood Substit Immobil Biotechnol 23:505–12
   PubMed Web of Science ®Google Scholar
• Noble CO, Guo Z, Hayes ME, et al. (2009). Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol 64:741–51
   PubMed Web of Science ®Google Scholar
• Noble RL. (1990). The discovery of the vinca alkaloids-chemotherapeutic agents against cancer. Biochem Cell Biol 68:1344–51
   PubMed Web of Science ®Google Scholar
• O'brien S, Schiller G, Lister J, et al. (2013). High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 31:676–83
   PubMed Web of Science ®Google Scholar
• Oku N, NambaY, Okada S. (1992). Tumor accumulation of novel RES-avoiding liposomes. Biochim Biophys Acta 1126:255–60
   PubMed Web of Science ®Google Scholar
• Owens DE 3rd, Peppas NA. (1996). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93–102
   Web of Science ®Google Scholar
• Rodriguez MA, Pytlik R, Kozak T, et al. (2009). Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer 115:3475–82
   PubMed Web of Science ®Google Scholar
• Rodriguez, Maria A, Fayad L, et al. (2005). Phase II study of sphingosomal vincristine in CHOP+/− rixtuximab for patients with aggressive non-Hodgkin's lymphoma (NHL): promising 3 year follow-up results in elderly patients. Blood (ASH Annual Meeting Abstracts) 106:943
   Google Scholar
• Rowinsky EK, Donehower RC. (1991). The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 52:35–84
   PubMed Web of Science ®Google Scholar
• Sarris AH, Hagemeister F, Romaguera J, et al. (2000). Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 11:69–72
   PubMed Web of Science ®Google Scholar
• Schmidt CF, BarenholzY, Thompson TE. (1977). A nuclear magnetic resonance study of sphingomyelin in bilayer systems. Biochemistry 16:2649–56
   PubMed Web of Science ®Google Scholar
• Sethi VS, Jackson DV Jr, White DR, et al. (1981). Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 41:3551–5
   PubMed Web of Science ®Google Scholar
• Shimshick EJ, McConnell H. (1973). Lateral phase separation in phospholipid membranes. Biochemistry 12:2351–60
   PubMed Web of Science ®Google Scholar
• Svoboda GH, Johnson Is, Gorman M, Neuss N. (1962). Current status of research on the alkaloids of Vinca rosea Linn. (Catharanthus roseus G. Don). J Pharm Sci 51:707–20
   PubMed Web of Science ®Google Scholar
• Thakkar HP, Baser A, Parmar MP, et al. (2012). Vincristine-sulphate-loaded liposome-templated calcium phosphate nanoshell as potential tumor-targeting delivery system. J Liposome Res 22:139–47
   PubMed Web of Science ®Google Scholar
• Thomas DA, Kantarjian H, Stock W, et al. (2009). Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer 115:5490–8
   PubMed Web of Science ®Google Scholar
• Thomas DA, Sarris A, Cortes J, et al. (2006). Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106:120–7
   PubMed Web of Science ®Google Scholar
• Tokudome Y, Oku N, Doi K, et al. (1996). Antitumor activity of vincristine encapsulated in glucuronide-modified long-circulating liposomes in mice bearing Meth A sarcoma. Biochim Biophys Acta 1279:70–4
   PubMed Web of Science ®Google Scholar
• Urruticoechea A, Alemany R, Balart J, et al. (2010). Recent advances in cancer therapy: an overview. Curr Pharm Des 16:3–10
   PubMed Web of Science ®Google Scholar
• Vaage J, Donovan D, Mayhew E, et al. (1993). Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes. Int J Cancer 54:959–64
   PubMed Web of Science ®Google Scholar
• Veronese FM, Pasut G. (2005). PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451–8
   PubMed Web of Science ®Google Scholar
• Webb MS, Harasym T, Masin D, et al. (1995). Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72:896–904
   PubMed Web of Science ®Google Scholar
• Webb MS, Saxon D, Wong FM, et al. (1998). Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372:272–82
   PubMed Web of Science ®Google Scholar
• Xu H, Ye F, Hu M, et al. (2014). Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection. Drug Deliv, Early Online: 1-10. doi: http://dx.doi.org/10.3109/10717544.2014.885998
   Google Scholar
• Yamauchi M, Tsutsumi K, Abe M, et al. (2007). Release of drugs from liposomes varies with particle size. Biol Pharm Bull 30:963–6
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Gervais A, Egorin MJ, et al. (2004). Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 53:329–36
   PubMed Web of Science ®Google Scholar
• Zhang L, Gao H, Chen L, et al. (2008). Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells. Cancer Lett 269:26–36
   PubMed Web of Science ®Google Scholar
• Zhigaltsev IV, Maurer N, Akhong QF, et al. (2005). Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release 104:103–11
   PubMed Web of Science ®Google Scholar
• Zhu G, Oto E, Vaage J, et al. (1996). The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity. Cancer Chemother Pharmacol 39:138–42
   PubMed Web of Science ®Google Scholar